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Antenatal iron supplementation and birth
weight in conditions of high exposure to
infectious diseases
Hans Verhoef1,2,3*, Martin N. Mwangi2,4, Carla Cerami1 and Andrew M. Prentice1
Abstract
Background: A recent cohort study among Papua New Guinean women surprisingly showed iron deficiency during
pregnancy to be associated with increased birth weight. These findings seemingly contradict previous trial evidence
that iron supplementation leads to increased birth weight, particularly in iron-deficient women, and hence require
explanation.
Main text: We have re-analysed data from a previous trial in Kenya and demonstrated that, because women who were
initially iron deficient respond better to iron supplementation, they show an increase in birthweight. There is evidence
that this benefit is decreased in iron-replete women, possibly due to the adverse effects of haemoconcentration that
can impair oxygen and nutrient transfer across the placenta. The Papua New Guinean results might be explained by a
similar differential response to the iron supplements that they all received.
Conclusions: Antenatal iron supplementation should ideally be administered in conjunction with measures to prevent,
diagnose and treat malaria given the propensity of pathogenic microorganisms to proliferate in iron-supplemented
individuals. However, even where services to prevent and treat malaria are poor, current evidence supports the
conclusion that the benefits of universal iron supplementation outweigh its risks.
Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1146-z.
Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1376-8.
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Background
A recent cohort study in Papua New Guinean pregnant
women reported an association between iron deficiency
(ferritin concentration < 15 μg/L) and higher birth weight
(by 230 g), particularly among primigravidae [1]. Despite
this finding, the authors conclude that it is essential to
provide both iron supplementation and effective malaria
chemoprophylaxis during pregnancy. This intriguing
report warrants close scrutiny since the result seems
to contradict current guidelines by the World Health
Organization (WHO) recommending daily oral iron
supplementation as part of antenatal care to prevent
maternal anaemia, puerperal sepsis, low birth weight
and preterm birth [2].
The WHO recommendation was based on a meta-
analysis of randomised trials in which antenatal iron
supplementation was suggested to lead to a slight increase
in birth weight (24 g, 95% CI − 3 g to 50 g) [3]. The mag-
nitude of this effect is probably grossly underestimated
because the meta-analysis was based on trials lacking a
true placebo arm, and in which women with anaemia or
iron deficiency were excluded, or were treated if they
developed anaemia or iron deficiency. Indeed, the only
placebo-controlled trial performed to date that enrolled
and followed women with iron deficiency or mild and
moderate anaemia was published after the WHO meta-
analysis [4]. This study found that iron supplementation
increased birth weight by 234 g (95% CI 116–351 g) in
iron-deficient women, consistent with the fact that ab-
sorption and utilisation of supplemental iron is enhanced
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in iron deficiency. Thus, the Papua New Guinean results
seem to be at variance with previous studies. What could
explain this divergence?
Antenatal iron supplementation and birth weight
We re-analysed data from our placebo-controlled trial in
pregnant Kenyan women [4] to assess to what extent iron
status at baseline (i.e. second trimester of pregnancy)
modified the magnitude of the effect of antenatal iron sup-
plementation on neonatal birth weight (see Additional file 1
for details and statistical methods). Maternal iron status
was assessed by plasma concentrations of ferritin and
soluble transferrin receptor, which were adjusted for
inflammation and Plasmodium infection. These markers
were used to calculate the body iron index, i.e. the natural
logarithm of the ratio of the adjusted ferritin concen-
tration to the adjusted transferrin receptor concentration.
This quantitative indicator has been shown to be linearly
associated with the size of the body iron store in iron-
replete individuals, and with the size of the functional
deficit that would need to be corrected before iron could
again be accumulated in the store in an iron-deficient
individual. Multiple fractional polynomial regression ana-
lysis showed that the birth weight response to adminis-
tered iron decreased with initial iron status (interaction
p = 0.04; Fig. 1). In addition, in women who received iron
supplementation, birth weight declined with iron status
(Fig. 1, blue line).
In the Papua New Guinea study, iron deficiency
was assessed at enrolment, at a mean gestational age
of 25 weeks (SD 4.2 weeks). All women in the study
were prescribed daily supplementation with iron and
folic acid. Consistent with our findings in Kenyan women,
iron-supplemented women who were initially iron defi-
cient had newborns with a higher birth weight than their
peers who were initially iron replete. What could explain
this phenomenon?
In normal pregnancies, plasma volume expansion leads
to a gradual reduction in haemoglobin concentration and
haematocrit levels in the gestational age period between 7
and 36weeks, despite concurrent increases in the total
erythrocyte and haemoglobin mass [5]. This haemo-
dilution is believed to increase oxygen delivery to tissues
and organs by reducing blood viscosity and thus increa-
sing blood velocity, particularly in the microcirculatory
vessels of the maternal intravillous space. Thus, there is an
optimum haematocrit level for oxygen delivery that is
lower than haematocrit values found in healthy, non-
pregnant women [6]. Haemodilution is vital for a
healthy pregnancy, and analyses of large numbers of
women of various races have shown that there is a
pronounced U-shaped curve with the lowest risk of low
birth weight and prematurity occurring well below the
WHO definition of anaemia [7].
In iron-deficient women, haemodilution without an
adequate supply of iron to the developing erythrocyte and
haemoglobin mass will likely result in placental in-
sufficiency, leading to low birth weight and prematurity.
This may explain the negative association that we found
between iron status and birthweight in women who were
not supplemented with iron (Fig. 1, red line). Conversely,
when iron deficiency is reversed by iron supplementation,
birth weight is increased. With increasing iron status,
however, the elevated haematocrit levels due to iron
Fig. 1 Effect of antenatal iron supplementation on neonatal birth weight in Kenya, by iron status at baseline. Iron status is indicated by body iron
index, i.e. the natural logarithm of the ratio of plasma concentrations of ferritin (μg/L) and soluble transferrin receptor (mg/L), both adjusted for
inflammation and Plasmodium infection (see text). Effects were adjusted for HIV infection and parity; other covariates were eliminated in the
multiple fractional polynomial regression (mfpi) procedure. Based on analysis of 391 Kenyan women. Left panel: Associations between birth
weight and body iron index for women who received supplementation with iron (blue line) or placebo (red line). The difference between these
lines is the treatment effect (i.e. the difference in mean birth weight between the iron group and the placebo group, with the placebo group
used as the reference) conditional to body iron index. The cumulative relative frequency distribution of the body iron index is indicated by the
grey line (and right Y-axis); 95% of women had values in the range between − 0.55 and 2.82. Right panels: treatment effect as a function of body
iron index, with corresponding 95% confidence bands and p value for interaction. The horizontal solid line indicates zero effect, whilst the
horizontal dashed line indicates the intervention effect as measured in a regression model without covariates other than the intervention (140 g)
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supplementation will increase blood viscosity. At some
point, haematocrit levels will exceed the optimum value,
resulting in a decreased delivery of oxygen (and other
nutrients) and decreasing birth weight (Fig. 1, blue line).
The crossing of red and blue lines in our figure suggests
that iron supplementation can even lead to a reduced
birth weight in women with high initial iron status, but
this may have affected very few women (grey line) and
supportive evidence is weak (see 95% confidence bands in
right panel).
Because all women in the Papua New Guinea study
were prescribed iron supplementation, it is impossible for
its effect to be determined. Based on the evidence
reviewed in the preceding sections, we speculate that birth
weight of children born to women who were initially
classified as iron deficient was increased by iron supple-
mentation. Thus, the results from the trials and the Papua
New Guinea study are not necessarily contradictory.
Antenatal iron supplementation and malaria risk
There is ample evidence that iron supplementation pre-
disposes towards the proliferation of pathogenic micro-
organisms. In vitro studies indicate that asexual blood
stages of P. falciparum preferably invade and propagate in
young erythrocytes, which transiently increase in numbers
when iron supplements are administered to iron-deficient
individuals [8, 9]. These findings may explain the transient
increase in malaria risk that has been observed in asso-
ciation with iron supplementation in infants and pre-
school children [9]. In addition, the enhanced blood
viscosity and decreased blood velocity ensuing from
iron supplementation might conceivably increase the
number of P. falciparum-parasitized erythrocytes that
cytoadhere to the vascular endothelium [6], thus avoiding
clearance by the spleen. Two large trials recently under-
taken to evaluate the effect of antenatal iron supplementa-
tion on maternal P. falciparum infection (reviewed by [9])
showed no evidence of an increased risk. Iron supplemen-
tation may be safer in women than in children because
women have higher levels of acquired immunity against
Plasmodium infection. Even among women who received
no intermittent preventive therapy, iron supplementation
appeared to increase birth weight (by 167 g) without an
apparent effect on P. falciparum infection risk [4].
Conclusion
Randomised trials offer superior methodology and should
be given higher priority in the hierarchy of evidence than
cohort studies because they minimise the risk of selection
bias. Benefits of universal iron supplementation in preg-
nancy are likely to vary with the prevalence of iron defi-
ciency [9] and are thus context specific. In low- and
middle-income countries, these benefits include increased
neonatal birth weight and infant iron stores, reduced
risk of severe maternal anaemia and maternal blood
transfusion and premature delivery [9]. Restriction of
iron supplementation to pregnant women who are
screened and diagnosed with iron deficiency during
antenatal clinics is not a feasible alternative to universal
iron supplementation [9].
Antenatal malaria prevention not only results in direct
health benefits to mothers and neonates, but has the
additional advantage that elimination of inflammation
associated with chronic Plasmodium infection may also
improve the absorption of non-haem iron from supple-
ments or dietary sources [10].
The efficacy and coverage of preventive measures
against malaria in pregnancy are generally low. For
example, among African countries that reported on
intermittent preventive treatment in pregnancy in 2016,
only 19% received the recommended minimum of three
doses of intermittent preventive treatment [11]. It seems
prudent to provide antenatal iron supplementation in
conjunction with measures to prevent, diagnose and
treat malaria. However, current evidence supports the
conclusion that the benefits of universal iron supple-
mentation outweigh the risks in conditions of high ex-
posure to infectious diseases, even with poor coverage of
preventive measures against malaria.
Additional file
Additional file 1: Methods to assess the influence of maternal body
iron status at baseline (i.e. second trimester of pregnancy) on the
magnitude of the effect of antenatal iron supplementation on neonatal
birth weight. (DOCX 19 kb)
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